Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship ProgramBusiness Wire • 02/27/26
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/26/26
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific CongressBusiness Wire • 02/26/26
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 02/25/26
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness Wire • 02/24/26
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/18/26
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial ResultsBusiness Wire • 02/11/26
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's DiseaseBusiness Wire • 02/04/26
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMDZacks Investment Research • 01/27/26
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy TranscriptSeeking Alpha • 01/26/26
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/26/26
Sarepta Therapeutics shares rise on positive Duchenne gene therapy dataProactive Investors • 01/26/26
Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy?Investors Business Daily • 01/26/26
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data showsReuters • 01/26/26
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne PatientsBusiness Wire • 01/26/26
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular DystrophyBusiness Wire • 01/23/26
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26